Classic polyarteritis nodosa is a multi-system, necrotizing vasculitis of small- and medium-sized muscular arteries in which involvement of the renal and visceral arteries is characteristic [
1]. Limited forms of polyarteritis nodosa have been described, and the skin is the most common organ to be involved [
2]. Cases of polyarteritis nodosa limited to gall bladder [
3], pancreas [
3], female [
4] and male [
5] genital tracts, kidneys [
6], and gastrointestinal tract [
7] have also been reported. Interest in these forms is based on their prognosis, which, in general, is more benign, and their quick response to corticosteroids alone [
2]. Polyarteritis nodosa limited to calf muscles is very rare and only 14 case reports have been published. It commonly affects middle-aged individuals (average age of 40 years), and there is no significant sex variation [
1]. Laboratory markers of inflammation (erythrocyte sedimentation rate and C-reactive protein) were elevated in all previous reports. Creatinine kinase is usually within normal limits. Only two reported cases had positive autoantibodies: a positive perinuclear anti-neutrophil cytoplasmic antibody in one [
8] and a positive anti-phospholipid antibody in the other [
9]. Unlike classic polyarteritis nodosa, which usually requires a combination of steroids and a cytotoxic drug such as cyclophosphamide for treatment [
1], limited polyarteritis nodosa usually responds well to treatment with corticosteroids alone with symptomatic relief within one week in most cases [
10,
11]. The dose of steroids used varied between 15 and 60 mg of prednisolone for initial treatment and 5 and 30 mg for maintenance. Two cases were reported to be resistant to corticosteroids but both of them responded well to intravenous immunoglobulin treatment and symptomatic response was rapid; however, one of the cases relapsed after six months and needed an increase in the oral steroid dose and the addition of methotrexate [
10]. Polyarteritis nodosa limited to calf muscles, fascia, and skin is a rare disease that runs a benign course and usually responds well to corticosteroid treatment. Resistant cases can be treated with cytotoxics such as azathioprine and methotrexate. The use of intravenous immunoglobulins is reported to induce a rapid symptomatic recovery in resistant cases, which may require cytotoxics for maintenance. The risk of progression to systemic disease is low, but close long-term follow-up of these patients may be advisable [
12].